Ibaragi Soichiro, Yoshioka Norie, Kishikawa Hiroko, Hu Jamie K, Sadow Peter M, Li Ming, Hu Guo-fu
Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA.
Mol Cancer Res. 2009 Mar;7(3):415-24. doi: 10.1158/1541-7786.MCR-08-0137. Epub 2009 Mar 3.
Angiogenin (ANG), originally identified as an angiogenic ribonuclease, has recently been shown to play a direct role in prostate cancer cell proliferation by mediating rRNA transcription. ANG is up-regulated in human prostate cancer and is the most significantly up-regulated gene in AKT-driven prostate intraepithelial neoplasia (PIN) in mice. Enhanced cell proliferation in the PIN lesions requires increased ribosome biogenesis, a multistep process involving an orchestrated production of ribosomal proteins and rRNA. AKT is known to enhance ribosomal protein production through the mammalian target of rapamycin pathway. However, it was unknown how rRNA is proportionally increased. Here, we report that ANG is essential for AKT-driven PIN formation and survival. We showed that up-regulation of ANG in the AKT-overexpressing mouse prostates is an early and lasting event. It occurs before PIN initiation and lasts beyond PIN is fully developed. Knocking down ANG expression by intraprostate injection of lentivirus-mediated ANG-specific small interfering RNA prevents AKT-induced PIN formation without affecting AKT expression and its signaling through the mammalian target of rapamycin pathway. Neomycin, an aminoglycoside that blocks nuclear translocation of ANG, and N65828, a small-molecule enzymatic inhibitor of the ribonucleolytic activity of ANG, both prevent AKT-induced PIN formation and reverse established PIN. They also decrease nucleolar organizer region, restore cell size, and normalize luminal architectures of the prostate despite continuous activation of AKT. All three types of the ANG inhibitor suppress rRNA transcription of the prostate luminal epithelial cells and inhibit AKT-induced PIN, indicating an essential role of ANG in AKT-mediated cell proliferation and survival.
血管生成素(ANG)最初被鉴定为一种血管生成性核糖核酸酶,最近研究表明它通过介导核糖体RNA(rRNA)转录在前列腺癌细胞增殖中发挥直接作用。ANG在人类前列腺癌中上调,并且是小鼠中由AKT驱动的前列腺上皮内瘤变(PIN)中上调最显著的基因。PIN病变中增强的细胞增殖需要增加核糖体生物合成,这是一个涉及核糖体蛋白和rRNA精心协调产生的多步骤过程。已知AKT通过雷帕霉素哺乳动物靶标途径增强核糖体蛋白的产生。然而,尚不清楚rRNA是如何相应增加的。在此,我们报告ANG对于AKT驱动的PIN形成和存活至关重要。我们发现,在过表达AKT的小鼠前列腺中ANG的上调是一个早期且持续的事件。它发生在PIN起始之前,并持续到PIN完全形成之后。通过前列腺内注射慢病毒介导的ANG特异性小干扰RNA敲低ANG表达可阻止AKT诱导的PIN形成,而不影响AKT表达及其通过雷帕霉素哺乳动物靶标途径的信号传导。新霉素是一种阻断ANG核转位的氨基糖苷类药物,N65828是一种ANG核糖核酸酶活性的小分子酶抑制剂,二者均能阻止AKT诱导的PIN形成并逆转已形成的PIN。尽管AKT持续激活,但它们还能减少核仁组织区、恢复细胞大小并使前列腺管腔结构正常化。所有这三种类型的ANG抑制剂均抑制前列腺管腔上皮细胞的rRNA转录并抑制AKT诱导的PIN,表明ANG在AKT介导的细胞增殖和存活中起关键作用。